TRVI Stock Forecast & Price Target

Trevi Therapeutics is a clinical-stage biopharmaceutical company with a positive outlook, thanks to their investigational therapy, Haduvio, which has shown promising results in reducing chronic cough frequency in patients with idiopathic pulmonary fibrosis and other interstitial lung diseases. They have a strong financial outlook with expected revenue and EBITDA growth, and a solid margin due to positive device sales. They have a potential for further growth with the adoption of Yellow Account and the durability of their processing margin. They also have potential for expansion into other markets such as elderly mass prophylaxis for shingles and treatment for epilepsy, making them an attractive stock for investment.

Trevi Therapeutics is currently facing several challenges, including regulatory risks and the loss of their market-building investment from GSK. Additionally, their current market opportunity for their investigational therapy Haduvio is heavily dependent on penetration rates, which could be impacted by potential future competition. This, coupled with the fact that most of their potential market for Haduvio usage is already on an antifibrotic, raises concerns about their ability to achieve peak-sales potential of more than $6B. Overall, with uncertainties surrounding their regulatory pathway and market potential, our financial analyst remains cautious about Trevi Therapeutics and holds a negative outlook on the stock.